The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015704:CD4 Antigens; D016827:CD8 Antigens; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005818:Genetic Engineering; D015316:Genetic Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D007370:Interferon Type I / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D019868:Kanamycin Kinase; D007680:Kidney Neoplasms / Q000628:therapy*; D017708:Leukocyte Transfusion; D007962:Leukocytes / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation*; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D010770:Phosphotransferases / Q000235:genetics*; D011994:Recombinant Proteins / Q000008:administration & dosage
D015704:CD4 Antigens; D016827:CD8 Antigens; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D010770:Phosphotransferases; D019868:Kanamycin Kinase